Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS of $2.38, well above the $1.13 consensus, while revenue rose 11.9% year-over-year to $15.19B, topping estimates by $420M.
Oncology product sales
The December quarter is shaping up to be a subdued one for India’s IT sector, with investors advised to focus...
U.S. equity futures fell sharply Sunday night after Federal Reserve Chair Jerome Powell confirmed that he is under investigation related...
In the Nifty500 pack, the closing prices of 21 stocks fell below their 200-day moving averages on January 9, according...
ET Intelligence Group: Oil marketing companies (OMCs) are set to drive earnings growth in the oil and gas sector in...
Allegiant Travel Co. will acquire Sun Country Airlines Holdings Inc. in a cash-and-stock deal valued at $1.5 billion including Sun...
The chief legal officer of Disc Medicine sold 6,500 shares of the company for $511,472 on Jan. 2. The sale...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
